Research graph
References from Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601. Local targets link to admitted publications; unresolved targets remain external evidence.
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
10.1182/blood-2005-06-2508 · 2006 · External reference
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
10.1056/nejmoa011795 · 2002 · External reference
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
10.1016/s1470-2045(06)70664-7 · 2006 · External reference
Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
10.1186/1756-9966-28-116 · 2009 · External reference
Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma
10.1007/s00277-010-0956-7 · 2010 · External reference
Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP21 or R-CHOP14
10.1371/journal.pone.0123978 · 2015 · External reference
Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review
10.1182/bloodadvances.2021004665 · 2021 · External reference
Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma
10.1007/s11136-010-9670-0 · 2010 · External reference
Vincristine-induced peripheral neuropathy: a mini-review
10.1016/j.neuro.2020.10.004 · 2020 · External reference
Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma
10.1007/s00277-015-2514-9 · 2016 · External reference
Impact of omission/reduction of vincristine from R-CHOP in treatment of DLBCL
10.1016/j.clml.2020.12.017 · 2021 · External reference
Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
10.1007/s00277-018-3437-z · 2018 · External reference
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
10.1016/s1470-2045(08)70002-0 · 2008 · External reference
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
10.3324/haematol.2022.282126 · 2023 · External reference
Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man
10.1212/wnl.18.9.875 · 1968 · External reference
Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas
10.1002/1097-0142(19940515)73:10<2515::aid-cncr2820731011>3.0.co;2-g · 1994 · External reference
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial
10.1182/bloodadvances.2020002567 · 2021 · External reference
Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma
10.3960/jslrt.51.1 · 2011 · External reference
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study
10.1200/jco.2004.03.213 · 2004 · External reference
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
10.1182/blood-2003-05-1545 · 2004 · External reference
A predictive model for aggressive non-Hodgkin's lymphoma
10.1056/nejm199309303291402 · 1993 · External reference
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
10.1182/blood-2006-08-038257 · 2007 · External reference
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
10.1111/j.1439-0507.2011.02158.x · 2012 · External reference
Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy
2014 · External reference
